Biomarker Testing, APOE4 Status and ARIA Risk Assessment In Alzheimer's Disease Patients: Insights from Australia and Hong Kong
In this study cohort, biomarker testing, APOE genotyping and ARIA risk assessment were limited among AD patients in Australia and HK, potentially hindering a robust identification of DMT candidates. Future research should investigate the implementation of these practices in larger samples to help advise where further education is needed.
Authors
- Hannah Brown (ORCID: https://orcid.org/0000-0003-2210-9624)
- Γεωργία Γιαννακοπούλου
- Nazira Jainis
- Hasifullah Ibrahim
- Joseph I Vindici
- Amber King
- Sandra Teoh
- Pieter De Richter
- Fleur Caponong
Institutions
- Hospital Kuala Lumpur (MY)
- IP Australia (AU)
- Ipsos (United States) (US)
- Ipsos (United Kingdom) (GB)
- University of Kuala Lumpur (MY)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_103681
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00